These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 8888809)

  • 41. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
    Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
    J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
    Feig SA; Krailo MD; Harris RE; Baum E; Holcenberg JS; Kaizer H; Steinherz L; Pendergrass TW; Saunders EF; Warkentin PL
    Med Pediatr Oncol; 1992; 20(2):124-9. PubMed ID: 1734217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
    Pashko S; Jacobs J; Santorsa J
    Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
    Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
    Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment and prognosis after late relapse in childhood acute lymphoblastic leukemia].
    Ikuta K; Fujioka K; Takahashi H; Sumita H; Sekiguchi H; Hanzawa N; Kai S; Kajigaya Y; Funabiki T; Okuyama T
    Rinsho Ketsueki; 1993 Jun; 34(6):712-7. PubMed ID: 8366572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.
    Saarinen-Pihkala UM; Parto K; Riikonen P; Lähteenmäki PM; Békàssy AN; Glomstein A; Möttönen M
    J Pediatr Hematol Oncol; 2012 May; 34(4):263-70. PubMed ID: 22246158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
    Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
    Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G; v Stackelberg A; Eckert C
    Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].
    Erttmann R; Bode U; Erb N; Forcadell de Dios P; Gutjahr P; Haas R; Kuhn N; Siewert H; Landbeck G
    Klin Padiatr; 1988; 200(3):200-4. PubMed ID: 3062256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
    Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
    Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
    Pautas C; Merabet F; Thomas X; Raffoux E; Gardin C; Corm S; Bourhis JH; Reman O; Turlure P; Contentin N; de Revel T; Rousselot P; Preudhomme C; Bordessoule D; Fenaux P; Terré C; Michallet M; Dombret H; Chevret S; Castaigne S
    J Clin Oncol; 2010 Feb; 28(5):808-14. PubMed ID: 20048183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idarubicin: an anthracycline antineoplastic agent.
    Cersosimo RJ
    Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
    Klumper E; Pieters R; den Boer ML; Huismans DR; Loonen AH; Veerman AJ
    Br J Cancer; 1995 Jun; 71(6):1188-93. PubMed ID: 7779709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.